These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 10886203)

  • 1. In vitro and in vivo studies with human carrier erythrocytes loaded with polyethylene glycol-conjugated and native adenosine deaminase.
    Bax BE; Bain MD; Fairbanks LD; Webster AD; Chalmers RA
    Br J Haematol; 2000 Jun; 109(3):549-54. PubMed ID: 10886203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The entrapment of polyethylene glycol-bound adenosine deaminase (Pegademase) in human carrier erythrocytes.
    Bax BE; Fairbanks LD; Bain MD; Simmonds HA; Chalmers RA
    Biochem Soc Trans; 1996 Aug; 24(3):442S. PubMed ID: 8878986
    [No Abstract]   [Full Text] [Related]  

  • 3. A 9-yr evaluation of carrier erythrocyte encapsulated adenosine deaminase (ADA) therapy in a patient with adult-type ADA deficiency.
    Bax BE; Bain MD; Fairbanks LD; Webster AD; Ind PW; Hershfield MS; Chalmers RA
    Eur J Haematol; 2007 Oct; 79(4):338-48. PubMed ID: 17680812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzyme replacement therapy of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase (PEG-ADA).
    Hershfield MS
    Immunodeficiency; 1993; 4(1-4):93-7. PubMed ID: 8167743
    [No Abstract]   [Full Text] [Related]  

  • 5. PEGylated Recombinant Adenosine Deaminase Maintains Detoxification and Lymphocyte Counts in Patients with ADA-SCID.
    Dorsey MJ; Rubinstein A; Lehman H; Fausnight T; Wiley JM; Haddad E
    J Clin Immunol; 2023 Jul; 43(5):951-964. PubMed ID: 36840835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzyme replacement therapy with polyethylene glycol-adenosine deaminase in adenosine deaminase deficiency: overview and case reports of three patients, including two now receiving gene therapy.
    Hershfield MS; Chaffee S; Sorensen RU
    Pediatr Res; 1993 Jan; 33(1 Suppl):S42-7; discussion S47-8. PubMed ID: 8433874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegademase bovine: replacement therapy for severe combined immunodeficiency disease.
    Lee CR; McKenzie CA; Webster KD; Whaley R
    DICP; 1991 Oct; 25(10):1092-5. PubMed ID: 1803799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of adenosine deaminase deficiency with adenosine deaminase combined with polyethylene glycol].
    Girault D; Le Deist F; Debré M; Pérignon JL; Herbelin C; Griscelli C; Sciudery D; Hershfield M; Fischer A
    Arch Fr Pediatr; 1992 Apr; 49(4):339-43. PubMed ID: 1497422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of polyethylene glycol-modified adenosine deaminase (PEG-ADA) therapy in two ADA-deficient children: measurement of erythrocyte deoxyadenosine triphosphate as a useful tool.
    Bory C; Boulieu R; Souillet G; Chantin C; Guibaud P; Hershfield MS
    Adv Exp Med Biol; 1991; 309A():173-6. PubMed ID: 1789201
    [No Abstract]   [Full Text] [Related]  

  • 10. Cerebral lymphoma in an adenosine deaminase-deficient patient with severe combined immunodeficiency receiving polyethylene glycol-conjugated adenosine deaminase.
    Kaufman DA; Hershfield MS; Bocchini JA; Moissidis IJ; Jeroudi M; Bahna SL
    Pediatrics; 2005 Dec; 116(6):e876-9. PubMed ID: 16263974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of an antibody to adenosine-deaminase (ADA) in an ADA-deficient patient receiving polyethylene glycol modified adenosine deaminase.
    Chun JD; Lee N; Kobayashi RH; Chaffee S; Hershfield MS; Stiehm ER
    Ann Allergy; 1993 Jun; 70(6):462-6. PubMed ID: 8507039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 24-Year Enzyme Replacement Therapy in an Adenosine-deaminase-Deficient Patient.
    Tartibi HM; Hershfield MS; Bahna SL
    Pediatrics; 2016 Jan; 137(1):. PubMed ID: 26684479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Polyethylene glycol-adenosine deaminase: a new adenosine deaminase deficiency therapy. Value of deoxyadenosine triphosphate determination for therapeutic monitoring].
    Bory C; Boulieu R; Souillet G; Hershfield MS
    Therapie; 1991; 46(4):323-6. PubMed ID: 1948809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase.
    Hershfield MS; Buckley RH; Greenberg ML; Melton AL; Schiff R; Hatem C; Kurtzberg J; Markert ML; Kobayashi RH; Kobayashi AL
    N Engl J Med; 1987 Mar; 316(10):589-96. PubMed ID: 3807953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular basis for paradoxical carriers of adenosine deaminase (ADA) deficiency that show extremely low levels of ADA activity in peripheral blood cells without immunodeficiency.
    Ariga T; Oda N; Sanstisteban I; Arredondo-Vega FX; Shioda M; Ueno H; Terada K; Kobayashi K; Hershfield MS; Sakiyama Y
    J Immunol; 2001 Feb; 166(3):1698-702. PubMed ID: 11160213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID).
    Chan B; Wara D; Bastian J; Hershfield MS; Bohnsack J; Azen CG; Parkman R; Weinberg K; Kohn DB
    Clin Immunol; 2005 Nov; 117(2):133-43. PubMed ID: 16112907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T lymphocyte ontogeny in adenosine deaminase-deficient severe combined immune deficiency after treatment with polyethylene glycol-modified adenosine deaminase.
    Weinberg K; Hershfield MS; Bastian J; Kohn D; Sender L; Parkman R; Lenarsky C
    J Clin Invest; 1993 Aug; 92(2):596-602. PubMed ID: 8349799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of elapegademase in patients with adenosine deaminase deficiency: A multicenter, open-label, single-arm, phase 3, and postmarketing clinical study.
    Onodera M; Uchiyama T; Ariga T; Yamada M; Miyamura T; Arizono H; Morio T
    Immun Inflamm Dis; 2023 Jul; 11(7):e917. PubMed ID: 37506145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Burkitt's lymphoma in a patient with adenosine deaminase deficiency-severe combined immunodeficiency treated with polyethylene glycol-adenosine deaminase.
    Husain M; Grunebaum E; Naqvi A; Atkinson A; Ngan BY; Aiuti A; Roifman CM
    J Pediatr; 2007 Jul; 151(1):93-5. PubMed ID: 17586199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyethylene glycol-modified adenosine deaminase improved lung disease but not liver disease in partial adenosine deaminase deficiency.
    Somech R; Lai YH; Grunebaum E; Le Saux N; Cutz E; Roifman CM
    J Allergy Clin Immunol; 2009 Oct; 124(4):848-50. PubMed ID: 19665771
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.